IN-DATE
AX1: Glaukos iAccess Precision Blade
Sign in to add this product to your favorites!
| Price: | $399.00 per box of 1 |
|---|---|
| Quantity: | |
| In Stock: | 4 box of 1 |
| Expiration: | 03-2027 |
| Express: | Need it tomorrow? Order in next 5 hours 9 minutes and choose overnight shipping at checkout. |
Additional Details
Glaukos iAccess Precision Blade
The iAccess® Precision Blade was developed by Glaukos in partnership with ophthalmic surgeons. iAccess® is designed to open the trabecular meshwork over an area >90° to directly access Schlemm’s canal. When medically necessary, precision goniotomy with iAccess® minimizes tissue disruption and is designed to preserve the eye’s natural blood-aqueous barrier.
Product Code: AX1
- 30-gauge, precision-lathed titanium nitride-coated blade creates ~220-µm-diameter incisions
- 300-µm-deep built-in safety backstop
- Ergonomic, custom-tapered handle designed for comfort and control
AccessGUDID Info
- FDA Product Code: HNN
- FDA Product Code Name: Knife, Ophthalmic
- GMDN Term Code: 46741
- GMDN Term Name: Ophthalmic knife, single-use
- GMDN Term Description: A hand-held manual ophthalmic surgical instrument designed to make precise incisions in the eye and surrounding tissues during ophthalmic surgery. It is typically designed as a one-piece instrument with a sharp, single-edged cutting blade at the distal tip and a handle at the proximal end. It can have a variety of blade edge shapes, e.g., phaco (blunt or sharp), crescent, straight, and micro-phaco (for micro incision cataract surgery). It is usually made of high-grade stainless steel and some types can employ silicon (i.e., a brittle metalloid material) blades. This is a single-use device.
Manufacturer
Glaukos is a medical technology company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases. The company is best known for pioneering minimally invasive glaucoma surgery (MIGS) with the iStent family of devices, which are implanted during cataract surgery to reduce intraocular pressure in patients with open-angle glaucoma. Glaukos has expanded its portfolio to include the iStent inject W and iStent infinite, as well as the iDose TR, a sustained-release intraocular drug delivery implant. The company is also advancing therapies in corneal cross-linking and retinal disease through its pipeline of biologics and sustained drug delivery platforms. Glaukos is focused on transforming the standard of care in chronic eye disease with safe, effective, and minimally invasive solutions.
